1h ago
Foreign investors turn net sellers by ₹298 crore as domestic institutions buy nearly ₹5,000 crore in Indian stocks
Foreign investors were net sellers of Indian equities by ₹298 crore on Thursday, ending a three-session buying streak. Domestic institutions bucked the trend with net purchases of nearly ₹5,000 crore. The Sensex and Nifty closed lower, weighed by declines in Reliance Industries’ finance unit and weakness in Bharti Airtel following remarks linked to Temasek. Some financial and jewellery stocks saw swings on expectations of policy changes.
1h ago
2d ago
Foreign investors buy ₹1,593.53 crore of Indian equities in second straight session
Foreign institutional investors were net buyers of Indian equities for a second consecutive session on Tuesday, with net purchases of ₹1,593.53 crore. Domestic institutional investors also stayed on the buying side, recording net purchases of ₹230.26 crore. Nifty ended the August series 1.5% higher at a two-week high after a sharp late-session rebound. Shriram Finance, IndiGo, Vodafone Idea, Paytm and IREDA rose, while Federal Bank slipped 3% on acquisition talk.
2d ago
8-14
US stocks open mixed on Aug. 14 as S&P 500 stays near record and eyes third straight weekly gain
US stocks opened mixed on Friday, with the S&P 500 near flat after closing at a record high in the previous session. July retail sales fell 0.6% month over month, far weaker than expectations for a 0.1% increase. Easing worries over inflation and interest rates helped lift technology and communication services, pushing the Nasdaq Composite up 0.2%. The Dow Jones Industrial Average slipped 0.1%.
8-14
8-14
Carlyle’s ₹1,750 crore Piramal Pharma 6% block deal likely called off; shares fall 3%
Private equity firm Carlyle was set to sell a 6% stake in Piramal Pharma via a ₹1,750 crore block deal, but the transaction is likely to have been cancelled. The stock fell about 3% after the update. As of the end of the June quarter, promoter entities held 34.8% while public shareholding stood at 64.72%. Piramal Pharma reported first-quarter revenue up 17.4% to ₹2,269.9 crore and EBITDA up 82.9% to ₹195.2 crore, lifting margin to 8.6% from 5.5%.
8-14